The UK Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new monthly safety bulletins, which aim to ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the ...

Entrada Therapeutics has secured authorisation from the UK MHRA to commence Phase I/II trial of ENTR-601-45 for treating DMD.

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new monthly safety bulletins, which aim to make medical device and medicine safety information clearer and more ...